Atea Pharmaceuticals AVIR
NASDAQ AVIR
$5.21 +0.03 (+0.58%)
At close: Sep 30, 2026 · 4:00 PM EDT

Atea Pharmaceuticals (AVIR) Current Deferred Revenue (2020 - 2021)

Updated

Atea Pharmaceuticals' Current Deferred Revenue came in at $192.18 million for Q3 2021, down 14.6% from the prior quarter.

Analysis

Atea Pharmaceuticals (AVIR) Current Deferred Revenue (2020 - 2021) Analysis & Trends

At the end of FY2020, Atea Pharmaceuticals' Current Deferred Revenue was $301.37 million.

  • Business Quant data shows AVIR's Current Deferred Revenue at $224.99 million (Q2 2021), $235.38 million (Q1 2021) and $301.37 million (Q4 2020) in the three quarters before Q3 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Atea Pharmaceuticals 417.87 Mn 417.87 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2021 192.18 Mn
Jun 30, 2021 224.99 Mn
Mar 31, 2021 235.38 Mn
Dec 31, 2020 301.37 Mn
API Access

Atea Pharmaceuticals Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=AVIR&period=max&api_key=YOUR_API_KEY